Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy.
Katarina Mirjačić MartinovićAna VuletićNevena Tišma MiletićSuzana MatkovićDušica GavrilovićAleksandra NinkovićVladimir JurišićNada BabovićPublished in: Journal of clinical pathology (2023)
The evidence in this study implies that baseline IL-6 could be a biomarker of DP and poor prognosis in BRAFwt MM patients treated with pembrolizumab.